Citations

Clear

6273 citation(s) found for "To, Andrew".

Application of Telemedicine in the Management of Cardiovascular Diseases: A Focus on Heart Failure
Mutirangura, Pornthira , Patel, Dil B. , Akram, Hassan , Hughes, Andrew , Arriola‐Montenegro, Jose , Koukousaki, Despoina , Money, Joel , Meyer, Mikhail , Harata, Mikako , Tóth, András , Alexy, Tamás , Patel, Dil , Meyer, Mikhail , Harata, Mikako , Alexy, Tamas , Hughes, Andrew M , Kosmopoulos, Marinos

Mayo Clinic

Reviews in Cardiovascular Medicine | July 2, 2025 | Volume: 26 | Issue: 6 | Pages: No page available

10.31083/rcm37835 | PMID 40630466 Get It

Heart failure (HF) is a complex clinical syndrome that represents one of the leading causes of morbidity and mortality in developed nations. It is well established that every HF-related hospital admission leads to worsened quality of life for the patient and their caregiver and also imposes a significant financial burden on society. Therefore, reducing hospital admissions for this population has emerged as a critical tactic over the past decades. Initial attempts at remote monitoring focused on self-reported vital signs and symptoms, yet these proved ineffective. Meanwhile, subsequent technological advancements have enabled the development of miniature sensors capable of detecting and monitoring a wide range of physiologically relevant parameters; some of these advancements have been integrated into implantable devices, such as pacemakers and defibrillators. However, noninvasive monitoring has recently emerged as an alternative option for patients with HF, offering early congestion detection without requiring an invasive procedure. This review aims to summarize implanted and noninvasive devices, their characteristics, monitored parameters, and potential limitations and challenges around their integration into routine clinical practices.
Comparing the Shape of the Maximal Expiratory Flow-Volume Curve Between Healthy Never Smokers and Asymptomatic Ex-Smokers
Regimbal, Riley J. , Dominelli, Paolo B. , Joyner, Michael J. , Joyner, Michael J , Ramsook, Andrew H , Hughes, Morgan A

Mayo Clinic

Physiology | July 1, 2025 | Volume: 40 | Issue: S1 | Pages: No page available

10.1152/physiol.2025.40.s1.0091 Get It

The maximal expiratory flow-volume (MEFV) curve is a valuable tool for assessing pulmonary function and diagnosing respiratory disease. Quantifying the shape of the MEFV curve may provide additional insight into pulmonary dysfunction compared to spirometry alone. We questioned if the shape of the MEFV curve could detect signs of abnormal lung emptying dynamics in asymptomatic ex-smokers when compared to never smokers free of cardiopulmonary disease. A retrospective analysis of routine spirometry from 22 asymptomatic ex-smokers (50% female) without a formal diagnosis of chronic obstructive pulmonary disease or other chronic respiratory disease was compared against 48 healthy never smokers (65% female). The shape of the MEFV curve was quantified via the slope-ratio method which generates a unitless value corresponding to the ratio between a line of tangency at a specific lung volume and a chord line intersecting the point of interest and residual volume. A SR of 1 would indicate a linear decrease in flow with decreasing lung volume, whereas a SR >1 or <1 would indicate a convex ( i.e., scooped) or concave ( i.e., bump) shape to the MEFV curve; respectively. Slope-ratio was assessed between 80-20% vital capacity in 2% vital capacity increments. A single average slope-ratio was taken as the mean of all slope-ratio values between 80-20% vital capacity per individual. Data are presented as mean ± SD. Patient demographics, including age, height and weight were not different between ex-smokers and never smokers (all p >0.05). No differences in pulmonary function between ex-smokers and never smokers were observed (FEV 1 : 89±22 vs. 95±20%predicted; FVC: 94±21 vs. 98±19%predicted; FEV 1 /FVC: 94±8 vs. 96±9%predicted, all p >0.05). The average slope-ratio was greater in ex-smokers compared to never smokers (1.74±0.29 vs. 1.45±0.41, p <0.0001). This difference was driven by a greater slope-ratio between 70-50% vital capacity (all, p <0.05). These preliminary data suggest slope-ratio analyses reveal a dysfunctional pattern of lung emptying in asymptomatic ex-smokers with no formal diagnosis of pulmonary disease compared to never smokers n that is not observed through spirometry alone. NSERC (PDF-577750-2023; AHR), NIH (HL139854; MJJ) This abstract was presented at the American Physiology Summit 2025 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process.
Cerebral Blood Flow Response to Different Breathing Patterns During Inspiratory Pressure Threshold Loading
Pruter, Wyatt W. , Joyner, Michael J. , Joyner, Michael J , Hughes, Morgan A , Ramsook, Andrew H

Mayo Clinic

Physiology | July 1, 2025 | Volume: 40 | Issue: S1 | Pages: No page available

10.1152/physiol.2025.40.s1.0757 Get It

Introduction: Regulation of cerebral blood flow (CBF) is vital for ensuring blood supply to cerebral tissue, and studies have shown that CBF increases to match the demands of whole-body exercise. Additionally, studies have shown that an inspiratory muscle metaboreflex induced by fatiguing inspiratory work causes a decrease in blood flow to limbs and splanchnic organs, presumably redirecting blood flow to the activated inspiratory muscles. However, it is unknown if the metaboreflex response is greater when targeting the diaphragm during inspiration as opposed to using all inspiratory muscles. We aimed to determine if middle cerebral artery velocity (MCAv), a surrogate for global CBF, was affected by inspiratory muscle metaboreflex, and if so, if MCAv is affected differently when targeting diaphragmatic pressure (PTL-diaphragm; PTL di ) vs targeting mouth pressure (PTL-mouth; PTL mo ). We hypothesized that MCAv will be preserved with fatiguing inspiratory work, in both PTL di and PTL mo breathing patterns. Methods: We studied 11 (5 females) participants without any cardiorespiratory, metabolic, or musculoskeletal diseases (36±9 yrs, FEV 1 /FVC: 100±8%predicted). Each participant had gastric and esophageal balloon catheters placed to measure respiratory pressures. Blood pressure was continuously recorded via finger photoplethysmography. Transcranial doppler ultrasound continuously recorded MCAv. Participants performed breathing trials through a custom-built inspiratory pressure loading (IPTL) device, designed to open when negative pressure was generated. Each trial was comprised of 15 breaths/minute, with each breath consisting of 70% inspiration and 30% expiration. Trial 1 involved 5 minutes of PTL mo targeting 60% of their maximal inspiratory pressure, and trial 2 consisted of 5 minutes of PTL di targeting 60% transdiaphragmatic pressure. CO 2 was administered during IPTL to avoid hypocapnia. Cerebrovascular conductance index (CVCi) was calculated from MCAv. A paired t-test compared the 2 trials, deltas are calculated from end task to baseline, and data are reported as mean±SD. Results: The transdiaphragmatic pressures (PTP di ) between the two trials were different (PTL mo : 5,051±2,620, PTL di : 7,082±2,200 cmH 2 O·s/min; p=0.009). The change inMAP were not different between trials (PTL mo : 8±4, PTL di : 13±9 ΔmmHg; p=0.10). There was no difference in the change in MCAv (PTL mo : 10.07±21.51, PTL di : 9.66±22.10 Δcm/s; p=0.96) or CVCi (PTL mo : 0.03±0.23, PTL di : -0.01±0.17 Δcm/s/mmHg; p=0.55) between the two trials. Conclusion: These findings suggest that the inspiratory muscle metaboreflex does not impair CBF regulation during IPTL; this is true regardless of inspiratory muscle recruitment. Further work should focus on continuing the breathing exercises until exhaustion. NIH (HL139854); NSERC (PDF-577750-2023) This abstract was presented at the American Physiology Summit 2025 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process.
Leg Vascular Conductance During Fatiguing Inspiratory Muscle Work Is Not Different Between Females And Males
Pruter, Wyatt W. , Joyner, Michael J. , Joyner, Michael J , Hughes, Morgan A , Ramsook, Andrew H

Mayo Clinic

Physiology | July 1, 2025 | Volume: 40 | Issue: S1 | Pages: No page available

10.1152/physiol.2025.40.s1.0601 Get It

Background: Fatiguing inspiratory muscle work can trigger the sympathetically-mediated respiratory muscle metaboreflex. Activating this reflex has been shown to increase blood pressure and heart rate while decreasing peripheral blood flow. Studies have shown females have an attenuated mean arterial pressure response (MAP) compared to males despite similar workloads to fatiguing inspiratory muscle work, suggesting females may have an attenuated respiratory muscle metaboreflex. However, the sex difference effects of respiratory muscle metaboreflex effects on resting limb vascular conductance (LVC) remains unknown. The purpose of this study was to investigate whether sex differences exist in LVC responses to fatiguing inspiratory muscle work. We hypothesize that males would exhibit a greater decrease in LVC compared to females. Methods: Eight healthy females (F; 35±11 years) and 8 healthy males (M; 31±6 years) completed the study. Participants completed a 5-minute baseline followed by a 5-minute inspiratory pressure threshold loading (IPTL) trial. The breathing pattern was set to 60% of their maximal inspiratory mouth pressure with a breathing frequency of 15 breaths/minute and an inspired duty cycle of 0.7 to activate the respiratory muscle metaboreflex. CO 2 was introduced into the inspired circuit to prevent hypocapnia. Continuous MAP (finger photoplethysmography) and heart rate (electrocardiogram) were recorded. Continuous blood velocity and diameters of the superficial femoral artery were measured using duplex ultrasonography. Leg blood flow (LBF) was calculated as the product of mean blood velocity and femoral artery cross-sectional area. LVC was calculated as LBF/mean arterial pressure. These data were averaged in 30-second segments and reported from 5-minute mark of IPTL (End-Task % of baseline). Groups were compared using Student’s t -test and analyzed using a two-way repeated-measures ANOVA. Results: Pulmonary function was within predicted ranges for all participants (FEV 1 /FVC: [F vs. M]: 100±8 vs. 100±9%predicted; P=0.919). Heart rate ([Baseline: F vs. M]: 70±13 vs. 73±8 bpm; P=0.571) and MAP (Baseline: [F vs. M]: 90±12 vs. 95±8 mmHg; P=0.378) were not different between females and males at baseline or throughout the IPTL trial (Group Main Effect: p>0.05 for both). Additionally, LBF decreased in response to IPTL but there was no difference between groups (End-Task: [F vs. M]: -31±33 vs. -21±24%baseline; Time Main Effect: P=0.012, Group Main Effect: P=0.352). When accounting for blood pressure, LVC also decreased during IPTL but was not different between females and males (End-Task: [F vs. M]: -37±30 vs. -33±24%baseline; Time Main Effect: p<0.001, Group Main Effect: P=0.655). Conclusion: These preliminary data suggest LVC decreases during a 5-minute period of fatiguing inspiratory work using IPTL; however, IPTL does not elicit variable LVC decreases between females and males. NIH (HL139854); NSERC (PDF-577750-2023) This abstract was presented at the American Physiology Summit 2025 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process.
Defining cervical spondylotic myelopathy surgical endotypes using comorbidity clustering: a Quality Outcomes Database cervical spondylotic myelopathy study
Howell, Harrison, Mummaneni, Praveen V., Chou, Dean , Bydon, Mohamad , Bisson, Erica F. , Shaffrey, Christopher I., Gottfried, Oren N., Asher, Anthony L. , Coric, Domagoj , Potts, Eric A. , Foley, Kevin T. , Wang, Michael Y. , Fu, Kai-Ming, Virk, Michael S. , Knightly, John J. , Meyer, Scott A., Upadhyaya, Cheerag D., Yen, Chun-Po , Uribe, Juan S. , Tumialán, Luis M. , Turner, Jay D. , Haid, Regis W., Chan, Andrew K. , Howell, Harrison J. , Howell, Harrison , Yang, Eunice, Mummaneni, Praveen V. , Shaffrey, Christopher I. , Park, Paul , Uribe, Juan S.

Mayo Clinic

Neurosurgical Focus | July 1, 2025 | Volume: 59 | Issue: 1 | Pages: E4

10.3171/2025.4.focus25207 | PMID 40591975 Get It

OBJECTIVE Coexisting medical conditions are increasingly prevalent in surgical populations. The impact of multiple comorbidities on patient-reported outcomes (PROs) and endotypes of frequently co-occurring conditions for cervical spondylotic myelopathy (CSM) remain unclear. This study explores whether CSM patients with multimorbidity have worse baseline and postoperative PROs and less functional improvement after surgery compared to those with few or no comorbidities. The authors also investigated whether distinct comorbidity endotypes exist among CSM surgical patients and whether they influence postoperative outcomes. METHODS The prospective Quality Outcomes Database (QOD) was used to assess patients undergoing surgery for CSM. Multimorbidity was defined as ≥ 2 chronic conditions, including diabetes, coronary artery disease, peripheral vascular disease, arthritis, chronic renal disease, chronic obstructive pulmonary disease, Parkinson’s disease, multiple sclerosis, depression, and anxiety. Baseline characteristics and 24-month PROs were assessed across multiple-comorbidity status, including modified Japanese Orthopaedic Association (mJOA), Neck Disability Index (NDI), visual analog scale for neck and arm pain, EQ-5D, and patient satisfaction scores. Clusters were identified from the full cohort using k-medoids, revealing subgroups with similar comorbidity endotypes. RESULTS The final cohort included 1141 CSM patients (83.1% reaching 24-month follow-up), with 761 (66.7%) having 0 or 1 comorbidity and 380 (33.3%) ≥ 2 comorbidities. The multimorbidity cohort was older (mean age 62.6 ± 11.2 vs 59.5 ± 12.0 years, p < 0.001), more likely to be female (52.9% vs 44.7%, p = 0.011), and had a higher BMI (mean 31.1 ± 6.7 vs 29.7 ± 6.2 kg/m 2 , p < 0.001). Multimorbidity patients exhibited worse mJOA, NDI, and EQ-5D scores at baseline and 24 months (p < 0.05). On multivariable analysis, the total number of comorbidities was not significantly associated with any PRO measures. Four comorbidity clusters were identified: low burden, arthritis, diabetes, and high burden. On one-way ANOVA, the baseline mJOA score was significantly different across clusters (p = 0.003). At 24 months, the mJOA score was significantly lower in the diabetes and high-burden endotypes. Twenty-four-month score change and minimal clinically important difference (MCID) achievement of all PROs remained similar across clusters (p > 0.05). CONCLUSIONS While patients with multimorbidity have worse baseline and postoperative PROs, they achieve similar functional and pain-related improvements following CSM surgery. Similarly, the comorbidity endotypes identified in this QOD cohort suggest that certain patterns of coexisting chronic conditions, such as overlapping diabetes and arthritis, are associated with different levels of disability but may not diminish the effectiveness of surgical intervention.
Assessing Analytical Performance and Correct Classification for Cardiac Troponin Deltas Across Diagnostic Pathways Used for Myocardial Infarction
Kavsak, Peter A. , Sharif, Sameer , Demian, Wael L. L., Belley‐Côté, Emilie P. , Blank, David , Knauer, Michael J. , Thorlacius, Laurel , Raizman, Joshua E., Huang, Yun , Beriault, Daniel R. , Fung, Angela W.S. , Yip, Paul S. F. , Clark, L., Abramson, Beth L. , Friedman, Steven , Atkinson, Paul , Suskin, Neville , Scheuermeyer, Frank , Humphries, Karin H. , Mondoux, Shawn , Ainsworth, Craig , Borges, Flávia K. , Worster, Andrew , McRae, Andrew D. , Jaffe, Allan S. , Belley-Cote, Emilie P , Knauer, Michael , Thorlacius, Laurel , Fung, Angela W S , Yip, Paul M , Friedman, Steven M , Suskin, Neville , Ainsworth, Craig , Borges, Flavia , McRae, Andrew , Jaffe, Allan S. , Beriault, Daniel R , Choi, Won-Shik, Taher, Jennifer , Shea, Jennifer L. , McLaren, Jesse T. T. , Chen‐Tournoux, Annabel , Sivilotti, Marco L.A. , Thiruganasambandamoorthy, Venkatesh , Aakre, Kristin M. , Kavsak, Peter

Mayo Clinic

Diagnostics | June 30, 2025 | Volume: 15 | Issue: 13 | Pages: 1652

10.3390/diagnostics15131652 | PMID 40647651 Get It

Background: In the emergency setting, many diagnostic pathways incorporate change in high-sensitivity cardiac troponin (hs-cTn) concentrations (i.e., the delta) to classify patients as low-risk (rule-out) or high-risk (rule-in) for possible myocardial infarction (MI). However, the impact of analytical variation on the delta for correct classification is unknown, especially at concentrations below and around the 99th percentile. Our objective was to assess the impact of delta variation for correct risk classification across the European Society of Cardiology (ESC 0/1 h and 0/2 h), the High-STEACS, and the common change criteria (3C) pathways. Methods: A yearlong accuracy study for hs-cTnT was performed where laboratories across Canada tested three patient-based samples (level 1 target value = 6 ng/L, level 2 target value = 9 ng/L, level 3 target value = 12 ng/L) monthly across 41 different analyzers. The assigned low-delta between levels 1 and 2 was 3 ng/L (i.e., 9 − 6 = 3 ng/L) and the assigned high-delta between levels 1 and 3 was 6 ng/L (i.e., 12 − 6 = 6 ng/L). The low- and high-deltas for each analyzer were determined monthly from the measured values, with the difference calculated from the assigned deltas. The obtained deltas were then assessed via the different pathways on correct classification (i.e., percent correct with 95% confidence intervals, CI) and using non-parametric analyses. Results: The median (interquartile range) difference between the measured versus assigned low-delta (n = 436) and high-delta (n = 439) was −1 ng/L (−1 to 0). The correct classification differed among the pathways. The ESC 0/1 h pathway yielded the lowest percentage of correct classification at 35.3% (95% CI: 30.8 to 40.0) for the low-delta and 90.0% (95% CI: 86.8 to 92.6) for the high-delta. The 3C and ESC 0/2 h pathways yielded higher and equivalent estimates on correct classification: 95.2% (95% CI: 92.7 to 97.0) for the low-delta and 98.2% (95% CI: 96.4 to 99.2) for the high-delta. The High-STEACS pathway yielded 99.5% (95% CI: 98.4 to 99.9) of correct classifications for the high-delta but only 36.2% (95% CI: 31.7 to 40.9) for the low-delta. Conclusions: Analytical variation will impact risk classification for MI when using hs-cTn deltas alone per the pathways. The 3C and ESC 0/2 h pathways have <5% misclassification when using deltas for hs-cTnT in this dataset. Additional studies with different hs-cTnI assays at concentrations below and near the 99th percentile are warranted to confirm these findings.
An Observational Analysis of a Large Cohort of Pneumocystis jirovecii Pneumonia
Pulsipher, Aaron M. , Vikram, Holenarasipur R. , Gotway, Michael B. , Cartin‐Ceba, Rodrigo , Henry, Kyle J, Johnson, Alec M, Gassner, Ryan R , Zhou, Kevin , Green, D., Thompson, Emily , Sen, Ayan , Lee, Augustine S. , Ham, Kealy R., Green, Danielle , Thompson, Emily R , Sen, Ayan , Lee, Augustine S , Ham, Kealy , Vikram, Holenarasipur R. , Gotway, Michael B , Pulsipher, Aaron M , Henry, Kyle J, Johnson, Alec M, Limper, Andrew H.

Mayo Clinic

Open Forum Infectious Diseases | June 28, 2025 | Volume: 12 | Issue: 7 | Pages: No page available

10.1093/ofid/ofaf390 | PMID 40708624 Get It

Abstract Background Pneumocystis jirovecii pneumonia (PCP) is increasingly seen in patients who are non-HIV immunocompromised hosts, yet modern risk factors and outcomes are poorly recognized and defined. Methods A retrospective review was conducted of adult patients who met criteria for proven or probable PCP from 2017 to 2024 across a large academic multicenter health system. The primary outcome was mortality among cohorts, defined by etiology of immunosuppression through univariate and age-adjusted logistic regression. Secondary analyses included trends in annual diagnoses and testing patterns. Results A total of 701 patients met criteria for inclusion, representing one of the largest clinically characterized cohorts of PCP to date. The median age was 65 years (IQR, 54–73) and 62% were male. The most common risk groups were hematologic malignancy (32.2%), solid tumor cancers receiving chemotherapy (22.4%), and autoimmune disease with immunosuppression (17.7%). Annual PCP diagnoses increased at a rate of 15.8% (95% CI, 8.9%–23.2%) in parallel with increased testing. Only 5.4% of patients were receiving prophylaxis at the time of diagnosis. Overall mortality was 20% (95% CI, 17%–23%) and highest in cirrhosis (adjusted odds ratio, 6.24; 95% CI, 2.84–13.69; P &lt; .001). Conclusions PCP in the current era affects a broad range of patients who are immunocompromised, with high associated mortality and low rates of prophylaxis. Patients with solid tumors and those with cirrhosis are at particularly high risk of mortality. These findings highlight the need to reassess and redefine PCP prophylaxis guidelines in specific populations and our understanding of who is at risk.
A Multiomics Study of Circulating Proteins and Kidney Stone Risk
Zhou, Le‐Ting , Stark, Isaac W. , Jayachandran, Muthuvel , Harris, Peter C. , Rule, Andrew D. , Koo, Kevin , Larson, Nicholas B. , Lieske, John C. , Larson, Nicholas B , Lieske, John C , Rule, Andrew D , Harris, Peter C , McDonnell, Shannon K.

Mayo Clinic

Journal of the American Society of Nephrology | June 27, 2025 | Volume: 36 | Issue: 12 | Pages: 2456-2468

10.1681/asn.0000000768 | PMID 40577066 Get It

Key Points Circulating proteins independently associated with kidney stone diagnosis are related to kidney stone matrix. Lower circulating uromodulin and higher scavenger receptor cysteine-rich domain-containing group B protein levels were associated with higher kidney stone risk, whereas kidney stone presence elevates plasma matrix metalloproteinase 7 level. The protective effect of uromodulin against kidney stones was independent of kidney function. Background Kidney stones are increasingly recognized as a systemic disorder with a high global prevalence. However, large proteomics studies are lacking. Methods An individual-level proteomics study with rigorous adjustments was performed on 35,331 UK Biobank participants to uncover the independent associations between 2922 circulating proteins and prevalent kidney stone disease. Mendelian randomization analysis was used to assess causal relationships. Findings were validated using genomic data from the Mayo Clinic Biobank ( N =43,744), concentration-response analysis, transcriptomics analyses, and additional genome-wide association studies. Results Nine plasma proteins were independently associated with a kidney stone diagnosis, including reduced uromodulin (UMOD; β , −0.10; 95% confidence interval [CI], −0.15 to −0.05) and elevated scavenger receptor cysteine-rich domain-containing group B protein (SSC4D; β , 0.28; 95% CI, 0.17 to 0.38) and were enriched in extracellular matrix pathways. Mendelian randomization analysis revealed that the presence of kidney stone contributed to elevated levels of matrix metalloproteinase 7. Conversely, lower plasma UMOD (odds ratio [OR], 0.93; 95% CI, 0.90 to 0.97) and higher plasma SSC4D (OR, 1.10; 95% CI, 1.02 to 1.18) were associated with kidney stone risk. These associations were consistently replicated in the Mayo Clinic Biobank dataset (UMOD; OR, 0.92; 95% CI, 0.86 to 0.98; SSC4D; OR, 1.13; 95% CI, 1.01 to 1.27) and further validated by a concentration-response analysis. Single-nucleus RNA sequencing and quantitative trait loci analyses confirmed consistent associations between thick ascending limb UMOD expression and stone former status and with blood and urine UMOD concentrations. Genome-wide association study analysis, adjusted for eGFR, suggested that the protective role of UMOD against kidney stones was independent of kidney function. Conclusions This study highlights significant associations between concentrations of specific blood proteins and a history of kidney stones. Several implicated proteins are related to kidney stone matrix, with UMOD independently associated with lower risk and SSC4D with higher risk of kidney stones.
Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment Consortium
Boyiadzis, Michael , Wei, Andrew H. , Freeman, Sylvie , Chyla, Brenda , Hersey, Sarah, Patel, Reshma, Maloney, Brian, Zumofen, Marie-Hélène Blanchet , Hoef, Marlies Van, Wulff, Beate, Obourn, Vanessa, Patel, Shalaka, Menezes, Daniel L. , Bengoudifa, Bourras‐Rezki, Dimier, Natalie , Wei, Andrew H , Paiva, Bruno , Kaspers, Gertjan J.L. , Shi, Qian , Prior, Thomas J. , Roboz, Gail J. , Prébet, Thomas

Mayo Clinic

Cancer | June 27, 2025 | Volume: 131 | Issue: 13 | Pages: No page available

10.1002/cncr.35960 | PMID 40576165 Get It

AbstractDespite advances in acute myeloid leukemia (AML) treatment, significant unmet medical needs remain. Surrogate end points for overall survival can accelerate the approval of novel therapies. Measurable residual disease (MRD) is a promising surrogate end point candidate, providing a sensitive and quantitative assessment of disease burden. Numerous studies have demonstrated that negative MRD status—across diverse methodologies, assessment timepoints and thresholds, patient subgroups, and clinical settings—independently predicts improved survival. Although MRD can inform therapeutic decisions at the patient level, its formal integration as a primary surrogate end point in regulatory frameworks for clinical trials requires rigorous validation. MRD Partnership and Alliance in AML Clinical Treatment (MPAACT) is a research consortium among industry and academic leaders. MPAACT actively engages with regulatory agencies, health technology assessment bodies, technology vendors, and patient groups to establish a pathway for validating MRD as a surrogate end point in AML clinical trials. For the current article, the authors reviewed the status of MRD assessment, its use in recent clinical trials, current MRD assessment methodologies, standardization, regulatory guidance, statistical approaches, and patient access considerations necessary for MRD to become a surrogate clinical trial end point. The extensive collaboration between MPAACT, global industry, and academic partners—including data sharing and resource integration—underscores the collective commitment to advancing AML therapies. Establishing MRD as a surrogate end point could accelerate the development and approval of innovative treatments, ultimately improving patient outcomes.
Secondary Peristalsis Is More Affected Than Primary Peristalsis by Increased Intragastric Pressure After Metabolic Bariatric Surgery: Findings From Functional Lumen Imaging Probe and High‐Resolution Esophageal Manometry
Perananthan, Varan , Hanscom, Mark, Razzak, Farah Abdul, Mrad, Rudy, Abboud, Donna Maria , Annan, Karim Al , Kassmeyer, Blake , Perananthan, Varan , Al Annan, Karim, Kerbage, Anthony , Storm, Andrew, Vargas Valls, Eric J, Abboud, Donna M , Ravi, Karthik , Hanscom, Mark , Razzak, Farah Abdul, Storm, Andrew C. , Vargas, Eric J. , Ghanem, Omar M. , Dayyeh, Barham K. Abu

Mayo Clinic

Neurogastroenterology & Motility | June 27, 2025 | Volume: 37 | Issue: 11 | Pages: No page available

10.1111/nmo.70110 | PMID 40572029 Get It

ABSTRACTIntroductionEsophageal dysmotility following metabolic bariatric surgery (MBS) may relate to decreased gastric compliance. We investigated high‐resolution esophageal manometry (HRM) and secondary peristalsis assessed by functional lumen imaging probe (FLIP) and their association with intragastric pressure after MBS.MethodsPatients undergoing HRM, FLIP, and barium esophagram (BE) after MBS were included. HRM metrics and proximal intragastric pressure at baseline (IGP baseline), during wet swallow‐induced esophagogastric junction relaxation (IGP EGJ opening), and following wet swallow‐induced esophagogastric junction opening with subsequent closure (IGP post EGJ closure) were measured. Contractile response was assessed during FLIP.ResultsForty patients (26 Roux en Y gastric bypass, 14 sleeve gastrectomy) with FLIP a median of 4 years after MBS, were identified. HRM was normal or consistent with ineffective esophageal motility (IEM) in 33 (82.5%) patients, while the contractile response on FLIP was abnormal (disordered/impaired, absent, or spastic reactive) in 28 (70%). Delayed emptying on BE was numerically more frequent with abnormal FLIP (6% vs. 0%, p = 0.08). IGP post‐EGJ closure (median 21.8 vs. 15 mmHg, p = 0.03) and ∆ IGP post‐EGJ closure—IGP baseline (median 4 vs. 0 mmHg, p = 0.02) were greater and predictive of abnormal contractility on FLIP (OR 1.11, 95% CI 1.00–1.2, p = 0.03 and OR 1.6, 95% CI 1.07–2.39, p = 0.003, respectively).DiscussionAbnormal contractility on FLIP, reflecting disordered secondary peristalsis, frequently occurs despite normal HRM findings after MBS. Secondary peristalsis may be associated with reduced gastric compliance, reflected by elevated proximal intragastric pressure. FLIP contractility could serve as an early marker for post‐MBS esophageal dysfunction.